A secondary analysis of FDG spatio-temporal consistency in the randomized phase II PET-boost trial in stage II-III NSCLC.

CONCLUSION: FDG redistributed boosting did not reduce FDG spatial consistency from pre-treatment to post-treatment, which was highly variable among patients. The study found high numbers of patients with lung inflammation after treatment. PMID: 29709378 [PubMed - as supplied by publisher]
Source: Radiotherapy and Oncology : journal of the European Society for Therapeutic Radiology and Oncology - Category: Radiology Authors: Tags: Radiother Oncol Source Type: research

Related Links:

In conclusion, tumor imaging phenotypes that are driven by somatic mutations may be predicted by radiomics based on PET/CT images.
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
AbstractObjectiveMetabolic tumor volume (MTV) and total lesion glycolysis (TLG) are imaging parameters derived from 18F-FDG PET/CT that have been proposed for risk stratification of cancer patients. The aim of our study was to test whether these whole-body volumetric imaging parameters may predict outcome in patients with non-small cell lung cancer (NSCLC).MethodsSixty-five patients (45 men, 20 women; mean age  ± SD, 65 ± 12 years), with histologically proven NSCLC who had undergone 18F-FDG PET/CT scan before any therapy, were included in the study. Imaging parameters includin...
Source: Annals of Nuclear Medicine - Category: Nuclear Medicine Source Type: research
Results from a phase III clinical trial comparing Keytruda (pembrolizumab) to standard chemotherapy shows the immunotherapy drug still has a long way to go as a viable treatment option for malignant pleural mesothelioma. Keytruda did not improve progression-free survival for mesothelioma patients who progressed after first-line chemotherapy. The disappointing results from the PROMISE-meso study were presented at the European Society of Medical Oncology (ESMO) annual meeting last week. It was the first randomized trial comparing progression-free survival between immunotherapy and first-line chemotherapy for mesothelioma p...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
ConclusionsThe combination of bemcentinib and pembro was well tolerated and showed promising efficacy in previously treated IO-na ïve NSCLC pts, particularly in those with AXL positive disease, including PD-L1 negative pts. mOS of >  12 mos is favorable compared with historical references in the NSCLC second-line setting.Clinical trial identificationNCT03184571.Legal entity responsible for the studyBerGenBio ASA.FundingBerGenBio ASA.DisclosureJ.M. Trigo Perez: Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Roche; Advisory / Consultancy, Speaker Bureau / E...
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
ConclusionsBlood-based detection of ALK fusions results in high ORR and clinical benefit in pts receiving alectinib. These data validate the clinical utility of blood-based NGS as an additional method to inform clinical decision-making in ALK+ NSCLC.Clinical trial identificationNCT03178552.Editorial acknowledgementMedical Writing support was provided by Nicola Griffin of Gardiner-Caldwell Communications and funded by F. Hoffmann-La Roche.Legal entity responsible for the studyF. Hoffmann-La Roche Ltd.FundingF. Hoffman-La Roche Ltd.DisclosureS.M. Gadgeel: Honoraria (self), Advisory / Consultancy: Ariad, AstraZeneca, Bristol-...
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
AbstractBackgroundThe KRASG12C mutation occurs in ∼13% of lung cancers (11% of non-small cell lung cancer [NSCLC]), 3% of colorectal cancer (CRC) and appendix cancers, and 1–3% of other solid tumors. KRASG12C is a driver of tumorigenesis, but there are no approved therapies targeting this mutation. AMG 510, a novel, orally administered small molecule, specifically and irreversibly inhibits KRASG12C by locking it in an inactive GDP-bound state. A phase 1, first-in-human, open-label, multicenter study is underway to evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of AMG 510 in adult patients ...
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
AbstractPositron emission tomography and computed tomography (PET –CT) is the non-invasive gold standard method for determining the oncological stage of patient with diagnosis of lung cancer. A correct preoperative staging is significant because only patients who do not have a history of regional or distant disease are those who will benefit from a surgical trea tment. However, due to the different values of the PET–CT in terms of sensitivity and specificity to evaluate the mediastinal lymph node involvement, it is often necessary to perform a surgical mediastinal sampling through a cervical video mediastinosco...
Source: Updates in Surgery - Category: Surgery Source Type: research
Abstract PURPOSE: Elderly patients with multiple primary or oligometastases (
Source: Journal of Applied Clinical Medical Physics - Category: Physics Authors: Tags: J Appl Clin Med Phys Source Type: research
In a patient who had been diagnosed of located squamous cell lung carcinoma, pneumonectomy and adjuvant chemotherapy were performed. Brain recurrence and subsequent lung metastatic disease were uncontrolled by neurosurgery, holocranial radiotherapy and first-line chemotherapy. In August 2015, appearance of leptomeningeal carcinomatosis triggered severe clinical deterioration and threatened the patient's life. Anti-PD1 immune checkpoint inhibitor Nivolumab was initiated in an attempt to stop tumour growth, achieving a spectacular brain and pulmonary complete response and clinical improvement, without serious adverse effects...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
ute;choux C Abstract Lung cancer treatment is a heavy workload for radiation oncologist and that field showed many evolutions over the last two decades. The issue about target volume was raised when treatment delivery became more precise with the development of three-dimensional conformal radiotherapy. Initially based upon surgical series, numerous retrospective and prospective studies aimed to evaluate the risk of elective nodal failure of involved-field radiotherapy compared to standard large field elective nodal irradiation. In every setting, locally advanced non-small cell lung cancer, localized non-small cell...
Source: Cancer Radiotherapie - Category: Cancer & Oncology Authors: Tags: Cancer Radiother Source Type: research
More News: Cancer & Oncology | Non-Small Cell Lung Cancer | PET Scan | Radiology | Study